Developer docs
API playgroundTry for free, no card

Search company profiles

Fesarius Therapeutics

Full company profile

uuid0002anu

Namestring
Fesarius Therapeutics
Legal namestring
Fesarius Therapeutics Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Fesarius Therapeutics Inc. is a New York–based, commercial-stage regenerative medicine company founded in 2015 as a spin-out from the Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine. The company's flagship product, DermiSphere hDRT, is a collagen-based hydrogel Dermal Regeneration Template that combines a less-dense collagen hydrogel with denser collagen microspheres to create differential resorption rates, enabling rapid vascularization (within 3 days in preclinical models), full wound bed incorporation, and stable neodermal tissue formation for the treatment of full-thickness skin loss. DermiSphere received FDA 510(k) clearance in January 2025, becoming the first and only hydrogel-class DRT available in the U.S. market, and the product is manufactured under an exclusive multi-year supply agreement with Regenity Biosciences.

The company monetizes DermiSphere through direct, quote-based sales to U.S. hospital systems, targeting plastic and reconstructive surgeons, wound care specialists, and burn/trauma centers. Its go-to-market is an enterprise field-sales motion supported by a customer service line (1-833-900-HDRT), medical affairs outreach, conference presence, and ASPS-channel relationships, with the American Society of Plastic Surgeons making its inaugural institutional investment in the company's June 2026 $20 million Series A alongside Jefferson Life Sciences, Johnson & Johnson Innovation – JJDC, and NY Ventures. Operating with a lean 1–10 employee footprint and using outsourced manufacturing, Fesarius is pursuing FDA Breakthrough Device Designation and a clinical-stage OneStep procedure that would combine DermiSphere with simultaneous split-thickness skin grafting, positioning the product to expand from a standalone DRT into a broader procedural platform.

Short descriptiontext

Fesarius Therapeutics is a New York–based regenerative medicine company that developed DermiSphere hDRT, the first FDA-cleared hydrogel dermal regeneration template for treating full-thickness skin loss. It sells directly to U.S. hospital systems and plastic/reconstructive surgeons under an exclusive manufacturing agreement with Regenity Biosciences.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dermal regeneration templates, wound care medical devices, regenerative medicine biomaterials, collagen hydrogel technology, skin tissue engineering
Industry2 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Wound Care Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1DermiSphere hDRT Product Sales
TypeOne Time License
Description

Fesarius generates revenue through the commercial sale of its FDA 510(k)-cleared DermiSphere hDRT hydrogel dermal regeneration template to hospital systems and surgeons for the treatment of full-thickness skin loss. The company is currently commercially active across multiple U.S. hospital systems following FDA clearance in January 2025 and the completion of its manufacturing agreement with Regenity Biosciences.

fesariustherapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Direct quotation-based pricing for healthcare providers
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based and not publicly disclosed. Healthcare providers are directed to contact customer service at 1-833-900-HDRT or via email for product pricing and ordering.

fesariustherapeutics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fesarius Therapeutics develops and commercializes DermiSphere hDRT, a proprietary collagen-based hydrogel Dermal Regeneration Template designed for the treatment of full-thickness skin loss. The product features a novel dual-density biphasic architecture combining a less-dense collagen hydrogel with denser collagen microspheres, enabling rapid vascularization and stable neodermal tissue formation. FDA 510(k) cleared in January 2025, DermiSphere is the first and only genuine hydrogel dermal regeneration template available on the U.S. market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Achieves complete vascularization and cell invasion within 3 days in preclinical porcine model
+3 more records
Product overview1 text field

Fesarius Therapeutics is a commercial-stage bioregenerative surgical company offering a single flagship product: DermiSphere™ hDRT (hydrogel Dermal Regeneration Template). This represents the first and only hydrogel-based dermal regeneration template available in the U.S. market, having received FDA 510(k) clearance in January 2025. The product uses a novel dual-density collagen hydrogel design with embedded collagen microspheres to accelerate wound healing for full-thickness skin loss by achieving rapid vascularization and complete cell invasion. The company became commercially active across multiple U.S. hospital systems following manufacturing agreement completion with Regenity Biosciences.

Product and service1 record
1DermiSphere hDRT (hydrogel Dermal Regeneration Template)
CategoryDermal Regeneration Template / Wound Care Medical Device
Description

The first and only hydrogel dermal regeneration template (hDRT) for treatment of full-thickness skin loss. Features a dual-density biphasic design combining a collagen-based hydrogel with denser collagen microspheres to facilitate rapid vascularization (within 3 days) and cellular invasion, enabling stable vascularized neodermal tissue formation. Used by plastic and reconstructive surgeons and wound care specialists in hospital systems.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-04-17
Description

Exclusive multi-year manufacturing and supply agreement with Regenity Biosciences, the leading development and manufacturing partner of regenerative technologies for the medical device community. Fesarius contracted with Regenity in 2022 to establish transfer and development of commercial manufacture of DermiSphere hDRT. Regenity has exclusive manufacturing responsibility for the product. Regenity is headquartered in Paramus, New Jersey with manufacturing in New Jersey and Groningen, the Netherlands.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology spin-out from the Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine in New York City, led by Dr. Jason Spector. Fesarius was founded in 2015 based on technology developed at this lab, with Dr. Spector serving as Chief of the Division of Plastic and Reconstructive Surgery at Weill Cornell Medicine.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Integra LifeSciences is the dominant incumbent in dermal regeneration templates through its Integra Dermal Regeneration Template product line and broader wound care portfolio. Directly comparable to Fesarius because it sells competing collagen-based DRTs used for full-thickness skin loss in reconstructive surgery and burn care.

TypeBroad incumbent
Description

Organogenesis is a leading regenerative medicine company selling skin and wound care products (Apligraf, Dermagraft, PuraPly, Affinity) used for chronic wounds, burns, and surgical repair. Comparable to Fesarius because it competes in advanced wound care and skin substitutes with biologics and regenerative templates sold into hospital systems.

TypeDirect peer
Description

MiMedx develops and commercializes regenerative skin and soft-tissue products (e.g., EpiFix, AmnioFix) used for wound healing and surgical reconstruction. Directly comparable to Fesarius because it serves the same plastic surgeon, wound care, and hospital customer base with tissue-based regenerative products for full-thickness and chronic wounds.

TypeBroad incumbent
Description

Smith+Nephew is a large medtech incumbent with an extensive advanced wound management portfolio (e.g., PICO single-use NPWT, skin substitutes and grafts) sold to hospitals and surgeons. Comparable to Fesarius as a broad wound care competitor that bundles products and competes for hospital formulary space.

TypeBroad incumbent
Description

ConvaTec is a global wound care and ostomy company selling advanced dressings, skin barriers, and regenerative products (e.g., InnovaMatrix) used in chronic and surgical wounds. Comparable to Fesarius because it competes in advanced wound care with biologic and matrix-based skin substitutes sold to hospitals.

TypeBroad incumbent
Description

Solventum (spun off from 3M in 2024) is a large diversified medtech player with an advanced wound care and surgical solutions portfolio. Comparable to Fesarius as a broad incumbent selling into the same hospital procurement and wound care channels.

TypeBroad incumbent
Description

Coloplast is a global medtech company with a sizable wound and skin care business (Biatain, Triademe) addressing chronic and surgical wounds. Comparable to Fesarius as an incumbent advanced wound care competitor pursuing similar hospital and specialty channel customers.

TypeDirect peer
Description

ACell, acquired by Integra LifeSciences, sells MatriStem UBM-based wound management devices for wound healing and surgical repair. Directly comparable to Fesarius as a competing extracellular matrix/skin substitute product used by surgeons for full-thickness wounds.

TypeOthers
Description

Regenity Biosciences is Fesarius's exclusive contract manufacturer and a broader regenerative technology developer producing collagen and biologic scaffolds for medical devices. Comparable as an ecosystem participant that supplies competing regenerative matrix products to other medical device companies.

TypeDirect peer
Description

Vivex Biologics markets tissue-based regenerative products (e.g., CYGNUS, AMNIOX) for wound healing, surgical repair, and orthopedic applications. Comparable to Fesarius because it sells amniotic and tissue-based skin substitutes and wound matrices into the same hospital and surgeon customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fesarius Therapeutics

Wound Care Medical Devicesfesariustherapeutics.com

Fesarius Therapeutics is a New York–based regenerative medicine company that developed DermiSphere hDRT, the first FDA-cleared hydrogel dermal regeneration template for treating full-thickness skin loss. It sells directly to U.S. hospital systems and plastic/reconstructive surgeons under an exclusive manufacturing agreement with Regenity Biosciences.

What Fesarius Therapeutics does

Fesarius Therapeutics Inc. is a New York–based, commercial-stage regenerative medicine company founded in 2015 as a spin-out from the Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine. The company's flagship product, DermiSphere hDRT, is a collagen-based hydrogel Dermal Regeneration Template that combines a less-dense collagen hydrogel with denser collagen microspheres to create differential resorption rates, enabling rapid vascularization (within 3 days in preclinical models), full wound bed incorporation, and stable neodermal tissue formation for the treatment of full-thickness skin loss. DermiSphere received FDA 510(k) clearance in January 2025, becoming the first and only hydrogel-class DRT available in the U.S. market, and the product is manufactured under an exclusive multi-year supply agreement with Regenity Biosciences.

The company monetizes DermiSphere through direct, quote-based sales to U.S. hospital systems, targeting plastic and reconstructive surgeons, wound care specialists, and burn/trauma centers. Its go-to-market is an enterprise field-sales motion supported by a customer service line (1-833-900-HDRT), medical affairs outreach, conference presence, and ASPS-channel relationships, with the American Society of Plastic Surgeons making its inaugural institutional investment in the company's June 2026 $20 million Series A alongside Jefferson Life Sciences, Johnson & Johnson Innovation – JJDC, and NY Ventures. Operating with a lean 1–10 employee footprint and using outsourced manufacturing, Fesarius is pursuing FDA Breakthrough Device Designation and a clinical-stage OneStep procedure that would combine DermiSphere with simultaneous split-thickness skin grafting, positioning the product to expand from a standalone DRT into a broader procedural platform.

Fesarius Therapeutics firmographics

Firmographics
Name
Fesarius Therapeutics
Legal name
Fesarius Therapeutics Inc.
Website
https://fesariustherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Fesarius Therapeutics is a New York–based regenerative medicine company that developed DermiSphere hDRT, the first FDA-cleared hydrogel dermal regeneration template for treating full-thickness skin loss. It sells directly to U.S. hospital systems and plastic/reconstructive surgeons under an exclusive manufacturing agreement with Regenity Biosciences.
Ownership category
akta.pro rank

Fesarius Therapeutics industry classification

Industry
Product category
Wound Care Medical Devices
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Dermal regeneration templates
  • Wound care medical devices
  • Regenerative medicine biomaterials
  • Collagen hydrogel technology
  • Skin tissue engineering

Where Fesarius Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Fesarius Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. DermiSphere hDRT Product Sales: Fesarius generates revenue through the commercial sale of its FDA 510(k)-cleared DermiSphere hDRT hydrogel dermal regeneration template to hospital systems and surgeons for the treatment of full-thickness skin loss. The company is currently commercially active across multiple U.S. hospital systems following FDA clearance in January 2025 and the completion of its manufacturing agreement with Regenity Biosciences.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDirect quotation-based pricing for healthcare providers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Fesarius Therapeutics product offering

Product offering

Core offering

Fesarius Therapeutics develops and commercializes DermiSphere hDRT, a proprietary collagen-based hydrogel Dermal Regeneration Template designed for the treatment of full-thickness skin loss. The product features a novel dual-density biphasic architecture combining a less-dense collagen hydrogel with denser collagen microspheres, enabling rapid vascularization and stable neodermal tissue formation. FDA 510(k) cleared in January 2025, DermiSphere is the first and only genuine hydrogel dermal regeneration template available on the U.S. market.

Product overview

Fesarius Therapeutics is a commercial-stage bioregenerative surgical company offering a single flagship product: DermiSphere™ hDRT (hydrogel Dermal Regeneration Template). This represents the first and only hydrogel-based dermal regeneration template available in the U.S. market, having received FDA 510(k) clearance in January 2025. The product uses a novel dual-density collagen hydrogel design with embedded collagen microspheres to accelerate wound healing for full-thickness skin loss by achieving rapid vascularization and complete cell invasion. The company became commercially active across multiple U.S. hospital systems following manufacturing agreement completion with Regenity Biosciences.

Differentiator

Problem solved

Functional benefit

Products and services

  • DermiSphere hDRT (hydrogel Dermal Regeneration Template) The first and only hydrogel dermal regeneration template (hDRT) for treatment of full-thickness skin loss. Features a dual-density biphasic design combining a collagen-based hydrogel with denser collagen microspheres to facilitate rapid vascularization (within 3 days) and cellular invasion, enabling stable vascularized neodermal tissue formation. Used by plastic and reconstructive surgeons and wound care specialists in hospital systems.

Quantifiable outcome

  • Achieves complete vascularization and cell invasion within 3 days in preclinical porcine model
  • +3 more outcomes

Companies that use Fesarius Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Fesarius Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Fesarius Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Regenity BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 17 April 2025Exclusive multi-year manufacturing and supply agreement with Regenity Biosciences, the leading development and manufacturing partner of regenerative technologies for the medical device community. Fesarius contracted with Regenity in 2022 to establish transfer and development of commercial manufacture of DermiSphere hDRT. Regenity has exclusive manufacturing responsibility for the product. Regenity is headquartered in Paramus, New Jersey with manufacturing in New Jersey and Groningen, the Netherlands.
  • Weill Cornell Medicine / Laboratory for Bioregenerative Medicine and SurgerycoreStrategic or Co-development PartnerTechnology spin-out from the Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine in New York City, led by Dr. Jason Spector. Fesarius was founded in 2015 based on technology developed at this lab, with Dr. Spector serving as Chief of the Division of Plastic and Reconstructive Surgery at Weill Cornell Medicine.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Fesarius Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Integra LifeSciences: Integra LifeSciences is the dominant incumbent in dermal regeneration templates through its Integra Dermal Regeneration Template product line and broader wound care portfolio. Directly comparable to Fesarius because it sells competing collagen-based DRTs used for full-thickness skin loss in reconstructive surgery and burn care.
  • Organogenesis: Organogenesis is a leading regenerative medicine company selling skin and wound care products (Apligraf, Dermagraft, PuraPly, Affinity) used for chronic wounds, burns, and surgical repair. Comparable to Fesarius because it competes in advanced wound care and skin substitutes with biologics and regenerative templates sold into hospital systems.
  • Smith+Nephew: Smith+Nephew is a large medtech incumbent with an extensive advanced wound management portfolio (e.g., PICO single-use NPWT, skin substitutes and grafts) sold to hospitals and surgeons. Comparable to Fesarius as a broad wound care competitor that bundles products and competes for hospital formulary space.
  • ConvaTec: ConvaTec is a global wound care and ostomy company selling advanced dressings, skin barriers, and regenerative products (e.g., InnovaMatrix) used in chronic and surgical wounds. Comparable to Fesarius because it competes in advanced wound care with biologic and matrix-based skin substitutes sold to hospitals.
  • Solventum (3M Health Care spinoff): Solventum (spun off from 3M in 2024) is a large diversified medtech player with an advanced wound care and surgical solutions portfolio. Comparable to Fesarius as a broad incumbent selling into the same hospital procurement and wound care channels.
  • Coloplast: Coloplast is a global medtech company with a sizable wound and skin care business (Biatain, Triademe) addressing chronic and surgical wounds. Comparable to Fesarius as an incumbent advanced wound care competitor pursuing similar hospital and specialty channel customers.

Direct peers

  • MiMedx: MiMedx develops and commercializes regenerative skin and soft-tissue products (e.g., EpiFix, AmnioFix) used for wound healing and surgical reconstruction. Directly comparable to Fesarius because it serves the same plastic surgeon, wound care, and hospital customer base with tissue-based regenerative products for full-thickness and chronic wounds.
  • ACell (Integra LifeSciences): ACell, acquired by Integra LifeSciences, sells MatriStem UBM-based wound management devices for wound healing and surgical repair. Directly comparable to Fesarius as a competing extracellular matrix/skin substitute product used by surgeons for full-thickness wounds.
  • Vivex Biologics: Vivex Biologics markets tissue-based regenerative products (e.g., CYGNUS, AMNIOX) for wound healing, surgical repair, and orthopedic applications. Comparable to Fesarius because it sells amniotic and tissue-based skin substitutes and wound matrices into the same hospital and surgeon customer base.

Others

  • Regenity Biosciences: Regenity Biosciences is Fesarius's exclusive contract manufacturer and a broader regenerative technology developer producing collagen and biologic scaffolds for medical devices. Comparable as an ecosystem participant that supplies competing regenerative matrix products to other medical device companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Fesarius Therapeutics social profiles

Digital presence

Fesarius Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fesarius Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Fesarius Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fesarius Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fesarius Therapeutics

What does Fesarius Therapeutics do?

Fesarius Therapeutics develops and commercializes DermiSphere hDRT, a proprietary collagen-based hydrogel Dermal Regeneration Template designed for the treatment of full-thickness skin loss. The product features a novel dual-density biphasic architecture combining a less-dense collagen hydrogel with denser collagen microspheres, enabling rapid vascularization and stable neodermal tissue formation. FDA 510(k) cleared in January 2025, DermiSphere is the first and only genuine hydrogel dermal regeneration template available on the U.S. market.

Is Fesarius Therapeutics a public or private company?

Fesarius Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fesarius Therapeutics founded?

Fesarius Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Fesarius Therapeutics based?

Fesarius Therapeutics is headquartered in New York, United States, in the North America region.

How does Fesarius Therapeutics make money?

One revenue line is on record: dermiSphere hDRT Product Sales.

Who are Fesarius Therapeutics's main competitors?

Broad incumbents on record are Integra LifeSciences, Organogenesis, Smith+Nephew, ConvaTec, Solventum (3M Health Care spinoff) and Coloplast. Direct peers are MiMedx, ACell (Integra LifeSciences) and Vivex Biologics. Regenity Biosciences is listed as an others.

Does Fesarius Therapeutics have an API?

No public API is recorded for Fesarius Therapeutics.

What industry is Fesarius Therapeutics in?

Fesarius Therapeutics's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFesarius Therapeutics to Showcase DermiSphere™ hDRT at Plastic Surgery The Meeting 2026Fesarius Therapeutics will showcase its DermiSphere™ hDRT at Plastic Surgery The Meeting 2026 in Houston, October 15–18. The dual-density collagen hydrogel is the first and only dermal regeneration template, and the company will host a scientific symposium and an ASPS Ventures roundtable.TrendHunter.comDermal Regeneration TemplatesFesarius Therapeutics introduced DermiSphere hDRT, a hydrogel dermal regeneration template designed to support wound healing and tissue regeneration, along with announcing a $20 million Series A funding round to boost commercialization and clinical development. The funding, backed by investors including Jefferson Life Sciences, Johnson & Johnson Innovation, NY Ventures, and ASPS Ventures, aims to enhance market expansion and advance the planned OneStep procedure. This innovative technology could significantly simplify the treatment process and reduce recovery times for complex wounds.Cornell ChronicleResearchers-turned-inventors recognized at Bearers of Innovation celebrationCornell University's Center for Technology Licensing held its Bearers of Innovation celebration on May 20, recognizing 82 lead inventors who submitted their first invention disclosure and 306 inventors whose technologies were licensed or optioned in fiscal years 2024 and 2025. The event highlighted Cornell's broader innovation track record, including over 1,000 licensed technologies, 20 new tech ventures launched in the last fiscal year, and $2.4 billion raised by the startup portfolio over five years. Featured commercialization journeys included Exostellar, a cloud-computing startup acquired by Qualcomm earlier this year, and Fesarius Therapeutics, whose DermiSphere wound-healing device received FDA 510(k) clearance in 2025.Pulse 2.0Fesarius Therapeutics Raises $20 Million Series A To Advance Dermal Repair TechnologyFesarius Therapeutics announced the closing of a $20 million Series A financing round led by Jefferson Life Sciences, with participation from Johnson & Johnson Innovation – JJDC, Empire State Development's NY Ventures, and the American Society of Plastic Surgeons (ASPS). The funding will support expansion of commercial infrastructure, pursue Breakthrough Device Designation, and advance clinical studies for its OneStep procedure using the FDA-cleared DermiSphere™ product. The company, which became the first hydrogel Dermal Regeneration Template available in the U.S. market after receiving FDA clearance in 2025, is already commercially active across multiple U.S. hospital systems and plans to use the capital to accelerate adoption and advance toward a pivotal clinical trial.PR NewswireFesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic SurgeonsFesariusTherapeutics announced the close of an oversubscribed $20 million Series A financing round, anchored by Jefferson Life Sciences and joined by Johnson & Johnson Innovation – JJDC, NY Ventures, and the American Society of Plastic Surgeons. The funding will support commercial expansion, pursue Breakthrough Device Designation, and advance clinical trials for the company's DermiSphere™ hydrogel Dermal Regeneration Template, which was FDA-cleared in 2025. The investment marks ASPS's inaugural institutional investment and positions Fesarius to accelerate growth in the $1.6 billion U.S. dermal regeneration market.BioSpaceFesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic SurgeonsFesariusTherapeutics closed an oversubscribed $20 million Series A led by Jefferson Life Sciences, with backing from NY Ventures and the American Society of Plastic Surgeons. Its FDA-cleared DermiSphere hydrogel device will fund commercial expansion and a clinical trial for a single-surgery procedure. The company aims to pursue Breakthrough Device Designation and label expansion.FinSMEsFesariusTherapeutics Raises $20M in Series A FundingFesariusTherapeutics raised $20M in Series A funding led by Jefferson Life Sciences, with participation from Johnson & Johnson Innovation, NY Ventures, and ASPS. The company will use the funds to expand operations and R&D, focusing on its FDA-cleared DermiSphere hydrogel wound management device.Dermatology TimesDermiSphere Offers More Affordable Treatment for Full Thickness Skin LossFesariusTherapeutics, Inc. has been awarded $1.83 million from the National Institutes of Health (NIH) to advance development of its DermiSphere dermal template for treating full thickness skin loss from burns, trauma, surgery, and chronic wounds. This is the company's third NIH research award, bringing total non-dilutive grant funding to nearly $4 million. The technology, which promotes native collagen deposition and vascularization, aims to eliminate the need for a second surgery required in current standard care, potentially reducing pain, scarring, and costs. The company plans to submit its FDA 510K application this year and begin commercialization in 2024.Precedence ResearchChronic Wound Care Medications Market Size to Hit USD 13.38 Billion by 2035The global chronic wound care medications market was valued at USD 6.80 billion in 2025 and is projected to reach USD 13.38 billion by 2035, growing at a CAGR of 7.00% due to rising prevalence of chronic non-healing wounds and demand for advanced therapeutic solutions. North America dominated the market with a 36.70% share in 2025, while Asia Pacific is expected to grow at the fastest rate through 2035. Recent developments include ConvaTec receiving regulatory clearance for its Aquacel™ ConvaFiber™ dressing in July 2025, Biomiq Inc launching PureGel™ in February 2025, and Fesarius Therapeutics receiving FDA 510(k) clearance in January 2025.AijournFesarius Therapeutics demonstrates the science that establishes DermiSphere™ hDRT in a class of its ownFesarius Therapeutics announced the publication of peer-reviewed preclinical evidence in Wound Repair and Regeneration journal demonstrating that its DermiSphere™ hDRT dermal regeneration template achieves vascularization and complete cell invasion within 3 days in a porcine animal model, significantly faster than leading market templates. The company, led by Chief Scientific Officer Yulia Sapir-Lekhovitser, highlighted that this speed advantage could reduce multiple surgical interventions, repetitive product applications, and overall healthcare delivery costs for full thickness wound treatment.